Abstract

A consensus has been reached in The Netherlands that all future medical costs should be included in economic evaluations. Furthermore, internationally, there is the recognition that in countries that adopt a societal perspective estimates of future nonmedical consumption are relevant for decision makers as much as production gains are. The aims of this paper are twofold: (1) to update the tool Practical Application to Include Future Disease Costs (PAID 1.1), based on 2013 data, for the estimation of future unrelated medical costs and introduce future nonmedical consumption costs, further standardizing and facilitating the inclusion of future costs; and (2) to demonstrate how to use the tool in practice, showing the impact of including future unrelated medical costs and future nonmedical consumption in a case-study where a life is hypothetically saved at different ages and 2 additional cases where published studies are updated by including future costs. Using the latest published cost of illness data from the year 2017, we model future unrelated medical costs as a function of age, sex, and time to death, which varies per disease. The Household Survey from Centraal Bureau Statistiek is used to estimate future nonmedical consumption by age. The updated incremental cost-effectiveness ratios (ICERs) from the case studies show that including future costs can have a substantial effect on the ICER, possibly affecting choices made by decision makers. This article improves upon previous work and provides the first tool for the inclusion of future nonmedical consumption in The Netherlands.

Highlights

  • Cost-utility analysis (CUA) is increasingly used to assess whether new interventions in healthcare yield sufficient value for money,[1] there are still several methodological issues that require attention

  • Splitting the incremental cost-effectiveness ratios (ICERs) equation into 3 ratios distinguishes the elements that are currently included in economic evaluation, related medical costs, and productivity costs, from the additional costs that are not usually considered: future unrelated medical costs and future costs of nonmedical consumption

  • We demonstrate the impact of including future costs on the ICER via 3 case studies

Read more

Summary

Introduction

Cost-utility analysis (CUA) is increasingly used to assess whether new interventions in healthcare yield sufficient value for money,[1] there are still several methodological issues that require attention. One such issue is the extent to which future costs should be included in CUAs,[2,3] where future costs are costs that arise from extending individuals’ lives and include all costs in the life-years gained (LYG) from an intervention. The discussion was extended with the more practical view that because future unrelated medical consumption benefits are generally included, the costs thereof should be included to be consistent.[6]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call